We are analyzing https://link.springer.com/article/10.1007/s00262-011-1028-0.

Title:
Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13 | Cancer Immunology, Immunotherapy
Description:
We undertook a comprehensive analysis of circulating myeloid-derived suppressor cells (MDSCs) and T regulatory cells (Tregs) in pancreatic, esophageal and gastric cancer patients and investigated whether MDSCs are an independent prognostic factor for survival. We evaluated a series of plasma cytokines and in particular re-evaluated the Th2 cytokine interleukin-13 (IL-13). Peripheral blood was collected from 131 cancer patients (46 pancreatic, 60 esophageal and 25 gastric) and 54 healthy controls. PBMC were harvested with subsequent flow cytometric analysis of MDSC (HLADR− Lin1low/− CD33+ CD11b+) and Treg (CD4+ CD25+ CD127low/− FoxP3+) percentages. Plasma IL-2, IL-4, IL-5, IL-6, IL-10, IL-12 (p70), IL-13, IL-17, G-CSF, IFN-γ, TNF-α and VEGF levels were analyzed by the Bio-Plex cytokine assay. Plasma arginase I levels were analyzed by ELISA. MDSCs and Tregs were statistically significantly elevated in pancreatic, esophageal and gastric cancer compared with controls, and MDSC numbers correlated with Treg levels. Increasing MDSC percentage was associated with increased risk of death, and in a multivariate analysis, MDSC level was an independent prognostic factor for survival. A unit increase in MDSC percentage was associated with a 22% increased risk of death (hazard ratio 1.22, 95% confidence interval 1.06–1.41). Arginase I levels were also statistically significantly elevated in upper gastrointestinal cancer patients compared with controls. There was Th2 skewing for cytokine production in all three diseases, and importantly there were significant elevations of the pivotal Th2 cytokine interleukin-13, an increase that correlated with MDSC levels.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Science
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't tell how the site generates income.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {🔍}

cancer, patients, cells, pancreatic, mdsc, mdscs, levels, arginase, article, significant, controls, gastric, pubmed, google, scholar, esophageal, cas, analysis, survival, suppressor, cell, cytokine, treg, percentage, table, myeloidderived, tumor, elevated, compared, prognostic, plasma, expression, data, factor, tregs, study, blood, increase, demonstrated, stage, tcell, correlation, received, independent, interleukin, foxp, assay, statistically, full, numbers,

Topics {✒️}

antigen-specific t-cell responses myeloid-derived suppressor cells inhibit graft-versus-host disease granulocyte-derived hydrogen peroxide chi^{2}_{\text{wald}} anti-cd33-pe cy5 article download pdf table 3 bio-plex assay anti-hladr-apc cy7 restores t-cell function suppress t-cell function anti-cd11b-pe cy7 tumor-induced cd11b+ splenocytes bio-plex cytokine assay transforming growth factor-beta anti-cd4-pe cy7 anti-cd25-apc cy7 t-cell cytokine production cd4+ t-cell population gastro-intestinal cancer health primary tumor arising ≤5 cm amino acid l-arginine anti-human monoclonal antibodies anti-cd8-pe cy5 lineage low/negative population stage ii–iii disease 54 age-/sex-matched controls subserving il-4-mediated signaling sex-matched healthy controls myeloid progenitor cells t-cell function th2 cytokine interleukin-13 il-2 receptor α-chain esophago-gastric cancer patients full access pancreatic carcinoma-conditioned medium bio-plex assay open access independent prognostic factor gastrointestinal research privacy choices/manage cookies monocytic mdscs express full immunosuppressive functionality autocrine growth factor renal cell carcinoma t-cell subset bone marrow controls wald test statistic received standard chemotherapy receptor negative cells

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13
         description:We undertook a comprehensive analysis of circulating myeloid-derived suppressor cells (MDSCs) and T regulatory cells (Tregs) in pancreatic, esophageal and gastric cancer patients and investigated whether MDSCs are an independent prognostic factor for survival. We evaluated a series of plasma cytokines and in particular re-evaluated the Th2 cytokine interleukin-13 (IL-13). Peripheral blood was collected from 131 cancer patients (46 pancreatic, 60 esophageal and 25 gastric) and 54 healthy controls. PBMC were harvested with subsequent flow cytometric analysis of MDSC (HLADR− Lin1low/− CD33+ CD11b+) and Treg (CD4+ CD25+ CD127low/− FoxP3+) percentages. Plasma IL-2, IL-4, IL-5, IL-6, IL-10, IL-12 (p70), IL-13, IL-17, G-CSF, IFN-γ, TNF-α and VEGF levels were analyzed by the Bio-Plex cytokine assay. Plasma arginase I levels were analyzed by ELISA. MDSCs and Tregs were statistically significantly elevated in pancreatic, esophageal and gastric cancer compared with controls, and MDSC numbers correlated with Treg levels. Increasing MDSC percentage was associated with increased risk of death, and in a multivariate analysis, MDSC level was an independent prognostic factor for survival. A unit increase in MDSC percentage was associated with a 22% increased risk of death (hazard ratio 1.22, 95% confidence interval 1.06–1.41). Arginase I levels were also statistically significantly elevated in upper gastrointestinal cancer patients compared with controls. There was Th2 skewing for cytokine production in all three diseases, and importantly there were significant elevations of the pivotal Th2 cytokine interleukin-13, an increase that correlated with MDSC levels.
         datePublished:2011-06-05T00:00:00Z
         dateModified:2011-06-05T00:00:00Z
         pageStart:1419
         pageEnd:1430
         license:https://creativecommons.org/licenses/by-nc/2.0
         sameAs:https://doi.org/10.1007/s00262-011-1028-0
         keywords:
            Myeloid-derived suppressor cell
            Cancer
            Prognostic factor
            Cytokine
            Interleukin-13
            Arginase
            Oncology
            Immunology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-011-1028-0/MediaObjects/262_2011_1028_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-011-1028-0/MediaObjects/262_2011_1028_Fig2_HTML.gif
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:60
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Rachel F. Gabitass
               affiliation:
                     name:University of Surrey
                     address:
                        name:Oncology Department, Postgraduate Medical School, University of Surrey, Surrey, UK
                        type:PostalAddress
                     type:Organization
                     name:St Luke’s Cancer Centre, Royal Surrey County Hospital
                     address:
                        name:St Luke’s Cancer Centre, Royal Surrey County Hospital, Surrey, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Nicola E. Annels
               affiliation:
                     name:University of Surrey
                     address:
                        name:Oncology Department, Postgraduate Medical School, University of Surrey, Surrey, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Deborah D. Stocken
               affiliation:
                     name:University of Birmingham
                     address:
                        name:Cancer Research UK Clinical Trials Unit, School of Cancer Sciences, University of Birmingham, Birmingham, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Hardev A. Pandha
               affiliation:
                     name:University of Surrey
                     address:
                        name:Oncology Department, Postgraduate Medical School, University of Surrey, Surrey, UK
                        type:PostalAddress
                     type:Organization
                     name:St Luke’s Cancer Centre, Royal Surrey County Hospital
                     address:
                        name:St Luke’s Cancer Centre, Royal Surrey County Hospital, Surrey, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Gary W. Middleton
               affiliation:
                     name:University of Surrey
                     address:
                        name:Oncology Department, Postgraduate Medical School, University of Surrey, Surrey, UK
                        type:PostalAddress
                     type:Organization
                     name:St Luke’s Cancer Centre, Royal Surrey County Hospital
                     address:
                        name:St Luke’s Cancer Centre, Royal Surrey County Hospital, Surrey, UK
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13
      description:We undertook a comprehensive analysis of circulating myeloid-derived suppressor cells (MDSCs) and T regulatory cells (Tregs) in pancreatic, esophageal and gastric cancer patients and investigated whether MDSCs are an independent prognostic factor for survival. We evaluated a series of plasma cytokines and in particular re-evaluated the Th2 cytokine interleukin-13 (IL-13). Peripheral blood was collected from 131 cancer patients (46 pancreatic, 60 esophageal and 25 gastric) and 54 healthy controls. PBMC were harvested with subsequent flow cytometric analysis of MDSC (HLADR− Lin1low/− CD33+ CD11b+) and Treg (CD4+ CD25+ CD127low/− FoxP3+) percentages. Plasma IL-2, IL-4, IL-5, IL-6, IL-10, IL-12 (p70), IL-13, IL-17, G-CSF, IFN-γ, TNF-α and VEGF levels were analyzed by the Bio-Plex cytokine assay. Plasma arginase I levels were analyzed by ELISA. MDSCs and Tregs were statistically significantly elevated in pancreatic, esophageal and gastric cancer compared with controls, and MDSC numbers correlated with Treg levels. Increasing MDSC percentage was associated with increased risk of death, and in a multivariate analysis, MDSC level was an independent prognostic factor for survival. A unit increase in MDSC percentage was associated with a 22% increased risk of death (hazard ratio 1.22, 95% confidence interval 1.06–1.41). Arginase I levels were also statistically significantly elevated in upper gastrointestinal cancer patients compared with controls. There was Th2 skewing for cytokine production in all three diseases, and importantly there were significant elevations of the pivotal Th2 cytokine interleukin-13, an increase that correlated with MDSC levels.
      datePublished:2011-06-05T00:00:00Z
      dateModified:2011-06-05T00:00:00Z
      pageStart:1419
      pageEnd:1430
      license:https://creativecommons.org/licenses/by-nc/2.0
      sameAs:https://doi.org/10.1007/s00262-011-1028-0
      keywords:
         Myeloid-derived suppressor cell
         Cancer
         Prognostic factor
         Cytokine
         Interleukin-13
         Arginase
         Oncology
         Immunology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-011-1028-0/MediaObjects/262_2011_1028_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-011-1028-0/MediaObjects/262_2011_1028_Fig2_HTML.gif
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:60
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Rachel F. Gabitass
            affiliation:
                  name:University of Surrey
                  address:
                     name:Oncology Department, Postgraduate Medical School, University of Surrey, Surrey, UK
                     type:PostalAddress
                  type:Organization
                  name:St Luke’s Cancer Centre, Royal Surrey County Hospital
                  address:
                     name:St Luke’s Cancer Centre, Royal Surrey County Hospital, Surrey, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Nicola E. Annels
            affiliation:
                  name:University of Surrey
                  address:
                     name:Oncology Department, Postgraduate Medical School, University of Surrey, Surrey, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Deborah D. Stocken
            affiliation:
                  name:University of Birmingham
                  address:
                     name:Cancer Research UK Clinical Trials Unit, School of Cancer Sciences, University of Birmingham, Birmingham, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Hardev A. Pandha
            affiliation:
                  name:University of Surrey
                  address:
                     name:Oncology Department, Postgraduate Medical School, University of Surrey, Surrey, UK
                     type:PostalAddress
                  type:Organization
                  name:St Luke’s Cancer Centre, Royal Surrey County Hospital
                  address:
                     name:St Luke’s Cancer Centre, Royal Surrey County Hospital, Surrey, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Gary W. Middleton
            affiliation:
                  name:University of Surrey
                  address:
                     name:Oncology Department, Postgraduate Medical School, University of Surrey, Surrey, UK
                     type:PostalAddress
                  type:Organization
                  name:St Luke’s Cancer Centre, Royal Surrey County Hospital
                  address:
                     name:St Luke’s Cancer Centre, Royal Surrey County Hospital, Surrey, UK
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:60
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Surrey
      address:
         name:Oncology Department, Postgraduate Medical School, University of Surrey, Surrey, UK
         type:PostalAddress
      name:St Luke’s Cancer Centre, Royal Surrey County Hospital
      address:
         name:St Luke’s Cancer Centre, Royal Surrey County Hospital, Surrey, UK
         type:PostalAddress
      name:University of Surrey
      address:
         name:Oncology Department, Postgraduate Medical School, University of Surrey, Surrey, UK
         type:PostalAddress
      name:University of Birmingham
      address:
         name:Cancer Research UK Clinical Trials Unit, School of Cancer Sciences, University of Birmingham, Birmingham, UK
         type:PostalAddress
      name:University of Surrey
      address:
         name:Oncology Department, Postgraduate Medical School, University of Surrey, Surrey, UK
         type:PostalAddress
      name:St Luke’s Cancer Centre, Royal Surrey County Hospital
      address:
         name:St Luke’s Cancer Centre, Royal Surrey County Hospital, Surrey, UK
         type:PostalAddress
      name:University of Surrey
      address:
         name:Oncology Department, Postgraduate Medical School, University of Surrey, Surrey, UK
         type:PostalAddress
      name:St Luke’s Cancer Centre, Royal Surrey County Hospital
      address:
         name:St Luke’s Cancer Centre, Royal Surrey County Hospital, Surrey, UK
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Rachel F. Gabitass
      affiliation:
            name:University of Surrey
            address:
               name:Oncology Department, Postgraduate Medical School, University of Surrey, Surrey, UK
               type:PostalAddress
            type:Organization
            name:St Luke’s Cancer Centre, Royal Surrey County Hospital
            address:
               name:St Luke’s Cancer Centre, Royal Surrey County Hospital, Surrey, UK
               type:PostalAddress
            type:Organization
      name:Nicola E. Annels
      affiliation:
            name:University of Surrey
            address:
               name:Oncology Department, Postgraduate Medical School, University of Surrey, Surrey, UK
               type:PostalAddress
            type:Organization
      name:Deborah D. Stocken
      affiliation:
            name:University of Birmingham
            address:
               name:Cancer Research UK Clinical Trials Unit, School of Cancer Sciences, University of Birmingham, Birmingham, UK
               type:PostalAddress
            type:Organization
      name:Hardev A. Pandha
      affiliation:
            name:University of Surrey
            address:
               name:Oncology Department, Postgraduate Medical School, University of Surrey, Surrey, UK
               type:PostalAddress
            type:Organization
            name:St Luke’s Cancer Centre, Royal Surrey County Hospital
            address:
               name:St Luke’s Cancer Centre, Royal Surrey County Hospital, Surrey, UK
               type:PostalAddress
            type:Organization
      name:Gary W. Middleton
      affiliation:
            name:University of Surrey
            address:
               name:Oncology Department, Postgraduate Medical School, University of Surrey, Surrey, UK
               type:PostalAddress
            type:Organization
            name:St Luke’s Cancer Centre, Royal Surrey County Hospital
            address:
               name:St Luke’s Cancer Centre, Royal Surrey County Hospital, Surrey, UK
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Oncology Department, Postgraduate Medical School, University of Surrey, Surrey, UK
      name:St Luke’s Cancer Centre, Royal Surrey County Hospital, Surrey, UK
      name:Oncology Department, Postgraduate Medical School, University of Surrey, Surrey, UK
      name:Cancer Research UK Clinical Trials Unit, School of Cancer Sciences, University of Birmingham, Birmingham, UK
      name:Oncology Department, Postgraduate Medical School, University of Surrey, Surrey, UK
      name:St Luke’s Cancer Centre, Royal Surrey County Hospital, Surrey, UK
      name:Oncology Department, Postgraduate Medical School, University of Surrey, Surrey, UK
      name:St Luke’s Cancer Centre, Royal Surrey County Hospital, Surrey, UK

External Links {🔗}(105)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.53s.

LINK . SPRINGER . COM {}